cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.14917850
title: Growth of Orange Trees

description: This is a replicate of the Orange dataset, that is distributed with the R package datasets to test the dataset package.

The Orange data frame has 35 rows and 3 columns of records of the growth of orange trees.

Source

Draper, N. R. and Smith, H. (1998), Applied Regression Analysis (3rd ed), Wiley (exercise 24.N).

Pinheiro, J. C. and Bates, D. M. (2000) Mixed-effects Models in S and S-PLUS, Springer.
DOI: 10.5281/zenodo.14917851
title: Growth of Orange Trees

description: This is a replicate of the Orange dataset, that is distributed with the R package datasets to test the dataset package.

The Orange data frame has 35 rows and 3 columns of records of the growth of orange trees.

Source

Draper, N. R. and Smith, H. (1998), Applied Regression Analysis (3rd ed), Wiley (exercise 24.N).

Pinheiro, J. C. and Bates, D. M. (2000) Mixed-effects Models in S and S-PLUS, Springer.
DOI: 10.15468/dl.da7p2f
title: Occurrence Download

description: A dataset listing the 31 species recorded in GBIF matching the query:
{
 "DatasetKey" : [
 "is The Brown University Foraminiferal Data Base (BFD)"
 ]
}

 The dataset's 31 records were derived from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003080-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.4xp5z9
title: Occurrence Download

description: A dataset containing 166260 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Betula nana L."
 ]
}

 The dataset includes 166260 records from 404 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003112-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.14906313
title: Improved structural modelling of antibodies and their complexes with clustered diffusion ensembles

description: The dataset contains the data used in the paper "Improved structural modelling of antibodies and their complexes with clustered diffusion ensembles". More specifically, the following files are available:



colabfold.zip : list of colabfold_batch results for the 54 antibodies discussed in the manuscript

alphaflow.zip : directory containing AlphaFlow ensembles for the 54 antibodies discussed in the manuscript (1000 models per PDB)

colabfold_antigen.zip : directory containing the colabfold_batch results for the 17 PDBs with low H3 loop PLDDT (low-80 dataset, see manuscript). Here the sequence of the antigen is also provided.

clustered_alphaflow_ensembles.zip : directory containing all the used clustered AlphaFlow ensembles for the 17 PDBs part of the LOW-80 dataset.

7*.tgz : files with all the docking runs described in the manuscript


several bash script are also available. They allow one to reproduce the results obtained in the paper.

In order to use them:



clone the repository https://github.com/haddocking/alphaflow-antibodies/ and follow the installation instructions

download all the zip and script files in the data directory of the downloaded repository (https://github.com/haddocking/alphaflow-antibodies/tree/main/data)

unzip the compressed zip files

execute the scripts in this order:



colabfold_analysis_cmds.sh / colabfold_heavy_analysis_cmds

colabfold_antigen_analysis_cmds / colabfold_antigen_heavy_analysis_cmds

alphaflow_analysis_cmds

alphaflow_clustered_ensemble_lines
DOI: 10.5281/zenodo.14906314
title: Improved structural modelling of antibodies and their complexes with clustered diffusion ensembles

description: The dataset contains the data used in the paper "Improved structural modelling of antibodies and their complexes with clustered diffusion ensembles". More specifically, the following files are available:



colabfold.zip : list of colabfold_batch results for the 54 antibodies discussed in the manuscript

alphaflow.zip : directory containing AlphaFlow ensembles for the 54 antibodies discussed in the manuscript (1000 models per PDB)

colabfold_antigen.zip : directory containing the colabfold_batch results for the 17 PDBs with low H3 loop PLDDT (low-80 dataset, see manuscript). Here the sequence of the antigen is also provided.

clustered_alphaflow_ensembles.zip : directory containing all the used clustered AlphaFlow ensembles for the 17 PDBs part of the LOW-80 dataset.

7*.tgz : files with all the docking runs described in the manuscript


several bash script are also available. They allow one to reproduce the results obtained in the paper.

In order to use them:



clone the repository https://github.com/haddocking/alphaflow-antibodies/ and follow the installation instructions

download all the zip and script files in the data directory of the downloaded repository (https://github.com/haddocking/alphaflow-antibodies/tree/main/data)

unzip the compressed zip files

execute the scripts in this order:



colabfold_analysis_cmds.sh / colabfold_heavy_analysis_cmds

colabfold_antigen_analysis_cmds / colabfold_antigen_heavy_analysis_cmds

alphaflow_analysis_cmds

alphaflow_clustered_ensemble_lines
DOI: 10.5281/zenodo.14917890
title: Global Water Desalination Equipment Market 2025 To 2034

description: Water Desalination Equipment Market Size, Trends and Insights By Source (Sea water, Brackish water, River water, Others), By Technology (Reverse Osmosis (RO), Multi-stage Flash (MSF) distillation, Multi-effect Distillation (MED), Others), By Application (Drinking Water Supply, Process Water, Irrigation Water, Others), By End Users (Municipal, Industrial, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033.

Reports Description

As per the current market research conducted by the CMI Team, the global Water Desalination Equipment Market is expected to record a CAGR of 8.7% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 18,023.8 Million. By 2033, the valuation is anticipated to reach USD 38,186.6 Million.

The water desalination equipment market involves the production and deployment of technologies and systems designed to convert seawater, brackish water, or wastewater into fresh water suitable for various applications. It encompasses a range of technologies including reverse osmosis, thermal desalination, and hybrid processes, catering to municipal, industrial, and agricultural sectors globally.

Key drivers include increasing water scarcity, regulatory support for water reuse, and technological advancements aimed at improving efficiency and reducing environmental impact. The market is characterized by innovation in membrane materials, energy recovery systems, and sustainable practices to meet the growing global demand for fresh water resources.

For more information, DOWNLOAD FREE SAMPLE Now at https://www.custommarketinsights.com/request-for-free-sample/?reportid=56241
DOI: 10.5281/zenodo.14917891
title: Global Water Desalination Equipment Market 2025 To 2034

description: Water Desalination Equipment Market Size, Trends and Insights By Source (Sea water, Brackish water, River water, Others), By Technology (Reverse Osmosis (RO), Multi-stage Flash (MSF) distillation, Multi-effect Distillation (MED), Others), By Application (Drinking Water Supply, Process Water, Irrigation Water, Others), By End Users (Municipal, Industrial, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033.

Reports Description

As per the current market research conducted by the CMI Team, the global Water Desalination Equipment Market is expected to record a CAGR of 8.7% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 18,023.8 Million. By 2033, the valuation is anticipated to reach USD 38,186.6 Million.

The water desalination equipment market involves the production and deployment of technologies and systems designed to convert seawater, brackish water, or wastewater into fresh water suitable for various applications. It encompasses a range of technologies including reverse osmosis, thermal desalination, and hybrid processes, catering to municipal, industrial, and agricultural sectors globally.

Key drivers include increasing water scarcity, regulatory support for water reuse, and technological advancements aimed at improving efficiency and reducing environmental impact. The market is characterized by innovation in membrane materials, energy recovery systems, and sustainable practices to meet the growing global demand for fresh water resources.

For more information, DOWNLOAD FREE SAMPLE Now at https://www.custommarketinsights.com/request-for-free-sample/?reportid=56241
DOI: 10.5519/qd.qnzx1w0e
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (1 records)
DOI: 10.15468/dl.3hwyhz
title: Occurrence Download

description: A dataset containing 12027 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Leontodon autumnalis Oeder, 1816"
 ]
}

 The dataset includes 12027 records from 162 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003119-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.u3et9b
title: Occurrence Download

description: A dataset containing 1984 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is NHMO DNA Bank Vascular plants collection",
 "TaxonKey is Cassiope tetragona (L.) D.Don"
 ]
}

 The dataset includes 1984 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003122-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.27791605
title: Fatal rhabdomyolysis and fulminant myocarditis with malignant arrhythmias after one dose of ipilimumab and nivolumab

description: Immune checkpoint inhibitors (ICIs) related myocarditis is a rare complication of modern immunotherapy. It can present as an asymptomatic subclinical condition or full-blown fulminant myocarditis with malignant arrythmias and cardiogenic shock. Myositis/rhabdomyolysis and/or myasthenic symptoms can be present concomitantly. We present a case of fatal fulminant myocarditis presenting with cardiac arrythmias and severe systolic dysfunction, with accompanying rhabdomyolysis after the first dose of ipilimumab and nivolumab immunotherapy. First working diagnosis of subacute late presenting acute myocardial infarction (ACS) was incorrect and the correct diagnosis was established only after additional testing and consultation. Treatment consisted of high-dose corticosteroids, intravenous immunoglobulins, sedation with mechanical ventilation, antibiotic coverage, hemodialysis, and sustained low-efficiency daily diafiltration (SLEDD) with CytoSorb or TheraNova membranes, and intra-aortic balloon pump mechanical cardiac support. No tangible improvement in the condition was observed during the whole treatment period and the patient died on the sixth day of intensive care treatment. This case report describes a 77-year-old man who experienced a life-threatening autoimmune inflammation and diminished function of cardiac muscle (myocarditis) and breakdown of muscle cells (rhabdomyolysis), after receiving immunotherapy for pleural (membrane that surrounds the lungs) cancer (mesothelioma). He was initially thought of having a heart attack (cardiac infarction), and only further testing proved aforementioned autoimmune disease. Despite intensive treatment his condition worsened progressively. The disease was ultimately fatal.
DOI: 10.6084/m9.figshare.27791605.v1
title: Fatal rhabdomyolysis and fulminant myocarditis with malignant arrhythmias after one dose of ipilimumab and nivolumab

description: Immune checkpoint inhibitors (ICIs) related myocarditis is a rare complication of modern immunotherapy. It can present as an asymptomatic subclinical condition or full-blown fulminant myocarditis with malignant arrythmias and cardiogenic shock. Myositis/rhabdomyolysis and/or myasthenic symptoms can be present concomitantly. We present a case of fatal fulminant myocarditis presenting with cardiac arrythmias and severe systolic dysfunction, with accompanying rhabdomyolysis after the first dose of ipilimumab and nivolumab immunotherapy. First working diagnosis of subacute late presenting acute myocardial infarction (ACS) was incorrect and the correct diagnosis was established only after additional testing and consultation. Treatment consisted of high-dose corticosteroids, intravenous immunoglobulins, sedation with mechanical ventilation, antibiotic coverage, hemodialysis, and sustained low-efficiency daily diafiltration (SLEDD) with CytoSorb or TheraNova membranes, and intra-aortic balloon pump mechanical cardiac support. No tangible improvement in the condition was observed during the whole treatment period and the patient died on the sixth day of intensive care treatment. This case report describes a 77-year-old man who experienced a life-threatening autoimmune inflammation and diminished function of cardiac muscle (myocarditis) and breakdown of muscle cells (rhabdomyolysis), after receiving immunotherapy for pleural (membrane that surrounds the lungs) cancer (mesothelioma). He was initially thought of having a heart attack (cardiac infarction), and only further testing proved aforementioned autoimmune disease. Despite intensive treatment his condition worsened progressively. The disease was ultimately fatal.
DOI: 10.6084/m9.figshare.28310056.v1
title: Recent advances in fluorescent gold nanocluster-based bioanalytical analysis and imaging in living cell

description: Ultrasmall and highly fluorescent gold nanoclusters (Au NCs) have been widely used for the construction of sensing and imaging platforms. Specifically, through a combination of surface functionalization and spectral analysis and/or imaging techniques, effective intracellular detection and imaging are realized. In this review, we summarize the recently adopted intracellular analysis and imaging events with Au NCs-based probes. The synthesis of Au NCs is briefly introduced based on stabilizer selection. The principles and applications of fluorometric intracellular detection systems toward different analytes, including small molecules and biomacromolecules, are presented by turnoff, turn-on, and ratiometric tactics. The cell imaging events are summarized based on conventional imaging and high-resolution imaging techniques, respectively. In the end, this review highlights the challenges of intracellular applications with Au NCs.
DOI: 10.6084/m9.figshare.27980419
title: Concurrent immunotherapy and radiation in cisplatin-ineligible patients with HNSCC: a systematic review & meta-analysis

description: Head and squamous cell carcinoma (HNSCC) in the locally advanced setting is challenging to treat and remains an area of significant morbidity and mortality. For patients who are cisplatin-ineligible and considered unresectable, there is no clear standard of care including the choice of radiosensitizer. OVID Medline, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched. Randomized clinical trials (RCTs) of cisplatin-ineligible unresectable HNSCC patients who were randomized to an immune checkpoint inhibitor concurrent with radiation compared to a control arm were included. Data was pooled and assessed using a random-effects model for the meta-analysis. Three eligible RCTs were identified and analyzed which comprised 594 patients whose median age ranged from 65–72 years. There was no difference in overall survival (pooled HR 1.02, 95% CI 0.76–1.37, <i>p</i> = 0.88) or PFS (pooled HR 0.92, 95% CI 0.68–1.23, <i>p</i> = 0.56). Grade greater than or equal to 3 adverse events were favored to be less in the immunotherapy arm. Immune-checkpoint inhibitors are not superior to cetuximab when used with definitive radiation in HNSCC. Further study is warranted, given its potential signal for non-inferior survival with less toxicity profile trends. Head and neck squamous cell carcinoma is a challenging cancer to treat. Cisplatin chemotherapy is often the preferred treatment combined with radiation, but alternatives are needed for patients who are not fit for this option. This study reviewed past clinical trials to understand how effective and safe immune checkpoint inhibitors are when combined with radiation therapy for these patients when compared to concurrent cetuximab and RT. Our results showed immune checkpoint inhibitors did not prove to be more effective than cetuximab, but they might offer a less toxic alternative. More research is needed to confirm these findings and explore new treatment options for patients who cannot receive cisplatin in combination with radiation.
DOI: 10.6084/m9.figshare.27980419.v1
title: Concurrent immunotherapy and radiation in cisplatin-ineligible patients with HNSCC: a systematic review & meta-analysis

description: Head and squamous cell carcinoma (HNSCC) in the locally advanced setting is challenging to treat and remains an area of significant morbidity and mortality. For patients who are cisplatin-ineligible and considered unresectable, there is no clear standard of care including the choice of radiosensitizer. OVID Medline, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched. Randomized clinical trials (RCTs) of cisplatin-ineligible unresectable HNSCC patients who were randomized to an immune checkpoint inhibitor concurrent with radiation compared to a control arm were included. Data was pooled and assessed using a random-effects model for the meta-analysis. Three eligible RCTs were identified and analyzed which comprised 594 patients whose median age ranged from 65–72 years. There was no difference in overall survival (pooled HR 1.02, 95% CI 0.76–1.37, <i>p</i> = 0.88) or PFS (pooled HR 0.92, 95% CI 0.68–1.23, <i>p</i> = 0.56). Grade greater than or equal to 3 adverse events were favored to be less in the immunotherapy arm. Immune-checkpoint inhibitors are not superior to cetuximab when used with definitive radiation in HNSCC. Further study is warranted, given its potential signal for non-inferior survival with less toxicity profile trends. Head and neck squamous cell carcinoma is a challenging cancer to treat. Cisplatin chemotherapy is often the preferred treatment combined with radiation, but alternatives are needed for patients who are not fit for this option. This study reviewed past clinical trials to understand how effective and safe immune checkpoint inhibitors are when combined with radiation therapy for these patients when compared to concurrent cetuximab and RT. Our results showed immune checkpoint inhibitors did not prove to be more effective than cetuximab, but they might offer a less toxic alternative. More research is needed to confirm these findings and explore new treatment options for patients who cannot receive cisplatin in combination with radiation.
DOI: 10.6084/m9.figshare.27991314
title: Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis

description: Immune checkpoint inhibitors (ICIs) are first-line treatment for melanoma. The incidence of musculoskeletal immune-related adverse events (MSK irAEs) remains unclear. To estimate the relative risk of MSK irAEs in melanoma patients treated with ICIs targeting programmed cell death-1 or its ligand PD-(L)1 as compared to placebo. We performed a systematic literature review including phase III randomized controlled trials of adult melanoma patients comparing a PD-(L)1 inhibitor to a placebo arm. Outcomes of interest included arthralgias, arthritis, back pain and myalgias. Meta-analysis was performed to estimate the pooled relative risk of MSK irAEs over the treatment course. Four RCTs met the inclusion criteria (<i>n</i> = 3,041 subjects). Use of PD-(L)1 inhibitors was associated with an increased risk of developing arthralgias (RR 1.30 [95% CI: 1.13–1.49]) and myalgias (RR 1.48 [95% CI: 1.17–1.87]) as compared to placebo. Back pain and arthritis were not reported. Use of PD-(L)1 inhibitors is associated with a significantly increased risk of arthralgias and myalgias in melanoma patients. The risk of back pain and arthritis is unknown. MSK irAEs can impact quality of life and should be considered, particularly in the adjuvant setting when risks and benefits are carefully weighed.
DOI: 10.6084/m9.figshare.27991314.v1
title: Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis

description: Immune checkpoint inhibitors (ICIs) are first-line treatment for melanoma. The incidence of musculoskeletal immune-related adverse events (MSK irAEs) remains unclear. To estimate the relative risk of MSK irAEs in melanoma patients treated with ICIs targeting programmed cell death-1 or its ligand PD-(L)1 as compared to placebo. We performed a systematic literature review including phase III randomized controlled trials of adult melanoma patients comparing a PD-(L)1 inhibitor to a placebo arm. Outcomes of interest included arthralgias, arthritis, back pain and myalgias. Meta-analysis was performed to estimate the pooled relative risk of MSK irAEs over the treatment course. Four RCTs met the inclusion criteria (<i>n</i> = 3,041 subjects). Use of PD-(L)1 inhibitors was associated with an increased risk of developing arthralgias (RR 1.30 [95% CI: 1.13–1.49]) and myalgias (RR 1.48 [95% CI: 1.17–1.87]) as compared to placebo. Back pain and arthritis were not reported. Use of PD-(L)1 inhibitors is associated with a significantly increased risk of arthralgias and myalgias in melanoma patients. The risk of back pain and arthritis is unknown. MSK irAEs can impact quality of life and should be considered, particularly in the adjuvant setting when risks and benefits are carefully weighed.
DOI: 10.6084/m9.figshare.28310056
title: Recent advances in fluorescent gold nanocluster-based bioanalytical analysis and imaging in living cell

description: Ultrasmall and highly fluorescent gold nanoclusters (Au NCs) have been widely used for the construction of sensing and imaging platforms. Specifically, through a combination of surface functionalization and spectral analysis and/or imaging techniques, effective intracellular detection and imaging are realized. In this review, we summarize the recently adopted intracellular analysis and imaging events with Au NCs-based probes. The synthesis of Au NCs is briefly introduced based on stabilizer selection. The principles and applications of fluorometric intracellular detection systems toward different analytes, including small molecules and biomacromolecules, are presented by turnoff, turn-on, and ratiometric tactics. The cell imaging events are summarized based on conventional imaging and high-resolution imaging techniques, respectively. In the end, this review highlights the challenges of intracellular applications with Au NCs.